1. Home
  2. SUPN vs CASH Comparison

SUPN vs CASH Comparison

Compare SUPN & CASH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SUPN
  • CASH
  • Stock Information
  • Founded
  • SUPN 2005
  • CASH 1954
  • Country
  • SUPN United States
  • CASH United States
  • Employees
  • SUPN N/A
  • CASH N/A
  • Industry
  • SUPN Biotechnology: Pharmaceutical Preparations
  • CASH Major Banks
  • Sector
  • SUPN Health Care
  • CASH Finance
  • Exchange
  • SUPN Nasdaq
  • CASH Nasdaq
  • Market Cap
  • SUPN 2.0B
  • CASH 1.9B
  • IPO Year
  • SUPN 2012
  • CASH N/A
  • Fundamental
  • Price
  • SUPN $42.00
  • CASH $75.34
  • Analyst Decision
  • SUPN Buy
  • CASH Buy
  • Analyst Count
  • SUPN 2
  • CASH 2
  • Target Price
  • SUPN $41.00
  • CASH $91.00
  • AVG Volume (30 Days)
  • SUPN 1.0M
  • CASH 196.2K
  • Earning Date
  • SUPN 08-05-2025
  • CASH 07-28-2025
  • Dividend Yield
  • SUPN N/A
  • CASH 0.27%
  • EPS Growth
  • SUPN 1411.53
  • CASH 4.46
  • EPS
  • SUPN 1.14
  • CASH 6.92
  • Revenue
  • SUPN $665,125,000.00
  • CASH $733,796,000.00
  • Revenue This Year
  • SUPN N/A
  • CASH $14.15
  • Revenue Next Year
  • SUPN $15.74
  • CASH $5.99
  • P/E Ratio
  • SUPN $37.58
  • CASH $10.90
  • Revenue Growth
  • SUPN 5.55
  • CASH 5.46
  • 52 Week Low
  • SUPN $29.16
  • CASH $62.79
  • 52 Week High
  • SUPN $43.73
  • CASH $86.00
  • Technical
  • Relative Strength Index (RSI)
  • SUPN 69.63
  • CASH 39.44
  • Support Level
  • SUPN $40.26
  • CASH $71.95
  • Resistance Level
  • SUPN $43.73
  • CASH $77.06
  • Average True Range (ATR)
  • SUPN 1.80
  • CASH 1.60
  • MACD
  • SUPN 0.31
  • CASH 0.06
  • Stochastic Oscillator
  • SUPN 84.13
  • CASH 43.12

About SUPN Supernus Pharmaceuticals Inc.

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

About CASH Pathward Financial Inc.

Pathward Financial Inc is a unitary savings and loan holding company. It's a wholly owned full-service banking subsidiary of Meta Financial, is both a community-oriented financial institution offering a variety of financial services to meet the needs of the communities it serves, and a payments company providing services on a nationwide basis. It operates through three reportable segments: Consumer: The Consumer segment includes the Partner Solutions business line, which collaborates with partners to navigate payment and lending needs; Commercial: The Commercial segment includes the Company's Commercial Finance business line, which helps businesses access funds needed to launch, operate, and grow; and Corporate Services. The majority of the revenue is generated from Consumer segment.

Share on Social Networks: